Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas
Citation and License
BMC Biology 2011, 9:72 doi:10.1186/1741-7007-9-72Published: 28 October 2011
Current interest in proteasome inhibitors for cancer therapy has stimulated considerable research efforts to identify the molecular pathway to their cytotoxicity with a view to identifying the mechanisms of sensitivity and resistance as well as informing the development of new drugs. Zhao and Vuori describe this month in BMC Biology experiments indicating a novel role of the adaptor protein p130Cas in sensitivity to apoptosis induced not only by proteasome inhibitors but also by the unrelated drug doxorubicin.
See research article: http:// http://www.biomedcentral.com/1741-7007/9/73 webcite